Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean Jacques; Cowey, C Lance; Lao, Christopher D; Schadendorf, Dirk; Dummer, Reinhard; Smylie, Michael; Rutkowski, Piotr; Ferrucci, Pier F; Hill, Andrew; Wagstaff, John; Carlino, Matteo S; Haanen, John B; Maio, Michele; Marquez-Rodas, Ivan; McArthur, Grant A; Ascierto, Paolo A; Long, Georgina V; Callahan, Margaret K; Postow, Michael A; Grossmann, Kenneth; Sznol, Mario; Dreno, Brigitte; Bastholt, Lars; Yang, Arvin; Rollin, Linda M; Horak, Christine; Hodi, F Stephen; Wolchok, Jedd D

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/21725

Title:	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Authors:	Larkin, James Chiarion-Sileni, Vanna Gonzalez, Rene Grob, Jean Jacques Cowey, C Lance Lao, Christopher D Schadendorf, Dirk Dummer, Reinhard Smylie, Michael Rutkowski, Piotr Ferrucci, Pier F Hill, Andrew Wagstaff, John Carlino, Matteo S Haanen, John B Maio, Michele Marquez-Rodas, Ivan McArthur, Grant A Ascierto, Paolo A Long, Georgina V Callahan, Margaret K Postow, Michael A Grossmann, Kenneth Sznol, Mario Dreno, Brigitte Bastholt, Lars Yang, Arvin Rollin, Linda M Horak, Christine Hodi, F Stephen Wolchok, Jedd D View more
Mesh:	Adult Aged Aged, 80 and over Antibodies, Monoclonal Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Disease-Free Survival Double-Blind Method Female Humans Intention to Treat Analysis Ipilimumab Male Melanoma Middle Aged Nivolumab Skin Neoplasms Tumor Burden View more
Issue Date:	2-Jul-2015
Citation:	N. Engl. J. Med..2015 Jul;(373)1:23-34
Abstract:	Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma.
PMID:	26027431
URI:	https://hdl.handle.net/20.500.12530/21725
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:

File	Description	Size	Format
PMC5698905.pdf		367.57 kB	Adobe PDF	View/Open

Show full item record